249 related articles for article (PubMed ID: 27896938)
1. Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
Chatterjee MS; Elassaiss-Schaap J; Lindauer A; Turner DC; Sostelly A; Freshwater T; Mayawala K; Ahamadi M; Stone JA; de Greef R; Kondic AG; de Alwis DP
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):29-39. PubMed ID: 27896938
[TBL] [Abstract][Full Text] [Related]
2. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
Ahamadi M; Freshwater T; Prohn M; Li CH; de Alwis DP; de Greef R; Elassaiss-Schaap J; Kondic A; Stone JA
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):49-57. PubMed ID: 27863186
[TBL] [Abstract][Full Text] [Related]
3. Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial.
Elassaiss-Schaap J; Rossenu S; Lindauer A; Kang SP; de Greef R; Sachs JR; de Alwis DP
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):21-28. PubMed ID: 27863143
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.
de Greef R; Elassaiss-Schaap J; Chatterjee M; Turner DC; Ahamadi M; Forman M; Cutler D; de Alwis DP; Kondic A; Stone J
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):5-7. PubMed ID: 27653180
[TBL] [Abstract][Full Text] [Related]
5. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
6. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.
Wang X; Feng Y; Bajaj G; Gupta M; Agrawal S; Yang A; Park JS; Lestini B; Roy A
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):40-48. PubMed ID: 28019090
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
10. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
Nishino M; Giobbie-Hurder A; Manos MP; Bailey N; Buchbinder EI; Ott PA; Ramaiya NH; Hodi FS
Clin Cancer Res; 2017 Aug; 23(16):4671-4679. PubMed ID: 28592629
[No Abstract] [Full Text] [Related]
11. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA
Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438
[TBL] [Abstract][Full Text] [Related]
12. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
Hauschild A; Eichstaedt J; Möbus L; Kähler K; Weichenthal M; Schwarz T; Weidinger S
Eur J Cancer; 2017 May; 77():84-87. PubMed ID: 28365530
[No Abstract] [Full Text] [Related]
13. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
14. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
18. Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.
Lindauer A; Valiathan CR; Mehta K; Sriram V; de Greef R; Elassaiss-Schaap J; de Alwis DP
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):11-20. PubMed ID: 27863176
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for treatment of refractory melanoma.
Bagcchi S
Lancet Oncol; 2014 Sep; 15(10):e419. PubMed ID: 25328942
[No Abstract] [Full Text] [Related]
20. [Not Available].
Eigentler TK
J Dtsch Dermatol Ges; 2015 Oct; 13(10):1055-6. PubMed ID: 26408485
[No Abstract] [Full Text] [Related]
[Next] [New Search]
